PREDIABETES MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2025-2032)

Global Prediabetes Market Size and Forecast – 2025 to 2032

The Global Prediabetes Market is estimated to be valued at USD 345.2 Million in 2025 and is expected to reach USD 709.9 Million by 2032, exhibiting a compound annual growth rate (CAGR) of 10.85% from 2025 to 2032. The market growth is primarily driven by the increasing prevalence of prediabetes worldwide, coupled with the rising awareness about the importance of early diagnosis and intervention to prevent the progression to type 2 diabetes.

Key Takeaways of the Global Prediabetes Market:

• In 2025, the Biguanides segment is expected to lead the global prediabetes market by drug class with a 21.2% share, driven by their strong efficacy, favorable safety profile, and affordability.
• The prescription-only drugs segment is projected to account for the highest market share by type at 54.3% in 2025, owing to their targeted action and reliable effectiveness.
• Oral administration remains the most preferred delivery route, dominating with an estimated 32.2% market share in 2025 due to its convenience and patient compliance.
• North America is expected to lead the market, holding a share of 37.3% in 2025. Asia Pacific is anticipated to be the fastest-growing region, with a market share of 23.2% in 2025.

Market Overview:

The market trend for the prediabetes market is characterized by the growing adoption of digital health solutions, such as mobile apps and wearable medical devices, which help individuals monitor their blood glucose levels, track their diet and exercise, and receive personalized recommendations. Additionally, there is a growing focus on developing novel therapeutic interventions, such as glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and sodium-glucose cotransporter-2 (SGLT-2) inhibitors, which have shown promising results in managing prediabetes and reducing the risk of progression to type 2 diabetes.

Currents Events and their Impact

Uncover macros and micros vetted on 75+ parameters: Get instant access to report

Segmental Analysis

To learn more about this report, Request sample copy

Prediabetes Market Insights, By Drug Class – Biguanides are the Leading Drug Class Backed by Strong Efficacy, Tolerability, and Cost Advantage

In terms of drug class, the Biguanides segment is expected to contribute the highest share of the market with 21.2% in 2025 owing to their proven efficacy, safety profile, and cost-effectiveness in managing prediabetes. Biguanides, particularly Metformin, have been widely prescribed by healthcare professionals due to their ability to reduce insulin resistance, improve glucose uptake, and suppress hepatic glucose production. Metformin's long-standing history of use and extensive clinical data demonstrating its effectiveness in preventing the progression of prediabetes to type 2 diabetes have further solidified its position as the first-line treatment option.

Moreover, Metformin's additional benefits, such as promoting weight loss, improving lipid profiles, and reducing the risk of cardiovascular complications, have made it an attractive choice for both patients and physicians. The drug's low cost and wide availability have also contributed to its high market share, making it accessible to a broad patient population. Furthermore, Metformin's favorable side effect profile, with minimal risk of hypoglycemia and good tolerability, has enhanced its adoption among prediabetic individuals.

Prediabetes Market Insights, By Type - Prescription-only Drugs are the Primary Treatment Choice Due to Precision, Potency, and Medical Oversight

In terms of type, the prescription-only drugs segment is expected to contribute the highest share of the market with 54.3% in 2025 due to their potency, targeted action, and proven efficacy in managing prediabetes. Prescription-only drugs, such as Metformin, Sulfonylureas, and DPP-4 inhibitors, are specifically designed to address the underlying pathophysiology of prediabetes, including insulin resistance and impaired glucose tolerance. These drugs undergo rigorous clinical trials and regulatory scrutiny to ensure their safety and effectiveness, instilling confidence among healthcare providers and patients alike.

The high market share of prescription-only drugs can be attributed to the personalized approach they offer in prediabetes management. Healthcare professionals can tailor the treatment regimen based on individual patient characteristics, such as age, comorbidities, and glycemic control, ensuring optimal outcomes. The ability to adjust dosages and monitor patients closely under medical supervision further enhances the efficacy and safety of these drugs.

Prediabetes Market Insights, By Route of Administration - Oral Administration is the Most Adopted Route for its Ease, Patient Acceptance, and Broad Availability

In the global prediabetes drug market, the oral segment is expected to hold the dominant share with 32.2% in 2025 and continues to be the most preferred route of drug delivery. This is primarily due to its convenience, ease of use, and high levels of patient compliance. For individuals managing a chronic but asymptomatic condition like prediabetes, oral formulations present a non-invasive, accessible, and cost-effective approach to long-term therapy.

Oral medications such as Metformin, a first-line pharmacologic agent, are widely prescribed for improving insulin sensitivity and reducing hepatic glucose production. Other drug classes—such as alpha-glucosidase inhibitors (e.g., Acarbose), DPP-4 inhibitors (e.g., Sitagliptin, Linagliptin), and SGLT2 inhibitors (e.g., Dapagliflozin, Empagliflozin)—are also available in oral form, further reinforcing this route’s prominence.

Macro & Micro Economic Factors Impacting Market Growth of Global Prediabetes Market

• Macroeconomic Factors- The rising prevalence of prediabetes and type 2 diabetes is intrinsically linked to broader macroeconomic trends. Rapid urbanization, aging populations, and global shifts toward sedentary lifestyles—especially in middle- and low-income countries—are major drivers . As urban centers expand and economies grow, diets high in processed and calorie-dense foods become commonplace, correlating with increasing obesity rates—a primary driver of prediabetes. Meanwhile, healthcare infrastructure investments and favorable government policies, particularly in North America and parts of Asia Pacific, are enhancing early screening and monitoring capabilities, further expanding the market for diagnostics, medications, and wearable monitoring devices
• Microeconomic Factors- At the patient and organizational level, microeconomic influences are shaping the market growth. Increased awareness among consumers and healthcare providers about early-stage glucose monitoring—boosted by mobile apps, continuous glucose monitors, and telehealth solutions—has driven demand. The widespread adoption of cost-effective first-line medications, especially metformin and GLP‑1 agonists, has also stimulated market expansion by offering validated intervention options. Moreover, lifestyle-related risk factors—such as rising obesity rates, sedentary behavior, and unhealthy eating—directly increase prediabetes prevalence, pushing individuals to purchase glucose monitoring devices, anti-diabetic medications, and nutrition/dietary products.

Regional Insights:

To learn more about this report, Request sample copy

North America Prediabetes Market Analysis and Trends

In North America, the dominance in the global prediabetes market can be attributed to several key factors with an estimated share of 37.3% in 2025. The region boasts a well-established healthcare infrastructure, coupled with high awareness about prediabetes and its associated risks. The presence of major pharmaceutical and biotechnology companies, such as Merck & Co., Inc., Novo Nordisk A/S, and Eli Lilly and Company, further solidifies the region's position. These companies actively invest in research and development, leading to the introduction of innovative products and therapies for prediabetes management.

Moreover, favorable government policies and reimbursement scenarios support the adoption of prediabetes diagnostic tests and treatments. The region's robust market ecosystem, including collaborations between industry players, healthcare providers, and research institutions, further fuels market growth. For instance, in December 2024, Memorial University of Newfoundland and the Young Men’s Christian Association (YMCA) at Canada, U.S. launched the “Small Steps for Big Changes” program in St. John’s. The 4-week initiative focuses on diet and exercise to help reverse prediabetes and prevent its progression to type 2 diabetes.

Asia Pacific Prediabetes Market Analysis and Trends

Meanwhile, the Asia Pacific region is expected to exhibit the fastest growth in the global prediabetes market with a share of 23.2% in 2025. This growth can be ascribed to the rising prevalence of prediabetes, driven by rapid urbanization, sedentary lifestyles, and changing dietary habits. Countries like China and India, with their large populations and increasing healthcare expenditure, significantly contribute to the market's expansion. Governments in the region are implementing initiatives to raise awareness about prediabetes and promote early diagnosis and intervention.

Additionally, the improving healthcare infrastructure and growing middle-class population with increased disposable income are driving the demand for prediabetes management products and services. Local companies, such as Tonghua Dongbao Pharmaceutical Co., Ltd. in China and Biocon Limited in India, are making significant strides in the market, offering affordable solutions tailored to regional needs.

Global Prediabetes Market Outlook for Key Countries:

U.S. Prediabetes Market Trends

The country's advanced healthcare system, coupled with extensive research and development activities, positions it as a key player in the market. The U.S. led the global prediabetes market, driven by rising obesity rates and growing adoption of digital health tools like mobile apps, wearables, and telehealth platforms that support early detection and lifestyle management. These trends are fueling the demand for effective prediabetes solutions.

For instance, in July 2024, the Icahn School of Medicine at Mount Sinai, a leading academic medical institution in New York, U.S. launched the Prediabetes/diabetes in youth Online Dashboard (POND). Built from NHANES data it offers the most comprehensive youth diabetes dataset to support research and prevention strategies for rising prediabetes and diabetes cases among young people.

Malaysia Prediabetes Market Trends

In Malaysia, the prediabetes market is shaped by rising prevalence driven by aging, urbanization, and lifestyle changes such as poor diet and physical inactivity. Higher risk is observed among Indians and Malays, urban residents, and women. Over 48% of adults are overweight or obese, and unhealthy habits are emerging even in children. In response, Malaysian health authorities are promoting early screening, lifestyle interventions, and pharmacotherapy (like metformin) as part of national prediabetes management efforts.

For instance, on May 21, 2025, Alpro Pharmacy, the largest prescription pharmacy chain, launched Alpro Stand Against Prediabetes, (ASAP) Programme to tackle the nation’s rising prediabetes risk. With 1 in 4 Malaysians affected, the campaign offers free HbA1c testing at over 300 outlets and promotes early screening, awareness, and professional care to prevent progression to type 2 diabetes.

Germany Prediabetes Market Trends

Germany continues to lead the European market for prediabetes, backed by its robust healthcare system, advanced medical research, and a proactive approach to disease prevention. The country's emphasis on early diagnosis and intervention, coupled with a high level of health awareness among the population, drives the demand for prediabetes management solutions. German companies, such as Boehringer Ingelheim and Bayer AG, play a significant role in the market, offering innovative products and collaborating with healthcare providers to improve patient outcomes.

For instance, in September 2024, Valbiotis and Nestlé Health Science decided to introduce a dietary supplement tailored for individuals with prediabetes and type-2 diabetes in Europe, following promising outcomes from a study demonstrating the product's effectiveness in improving critical indicators of glucose metabolism.

India Prediabetes Market Trends

India's market for prediabetes is rapidly expanding, driven by the country's large population, increasing urbanization, and rising prevalence of risk factors such as obesity and sedentary lifestyles. The government's initiatives to strengthen healthcare infrastructure and improve access to affordable medicines are key factors supporting market growth. Indian companies, such as Biocon Limited and Dr. Reddy's Laboratories Ltd., are making significant contributions to the market, offering cost-effective solutions for prediabetes management.

For instance, in November 2024, Redcliffe Labs, a leading Indian diagnostics provider, launched the Prediabetes Risk Checker on its Android app as part of its “Beat the Sugar Trap” campaign. The digital tool offers personalized risk assessments using lifestyle and genetic inputs, aiming to boost early detection and preventive care for diabetes and prediabetes in India.

Market Players, Key Developments, and Competitive Intelligence:

To learn more about this report, Request sample copy

Key Developments:

• On March 17, 2025, Morepen Laboratories, a leading Indian pharma firm, launched Empamore, a cost-effective empagliflozin-based drug for type 2 diabetes, heart failure, and kidney disease, supporting affordable care in the global prediabetes market.
• In August 2024, Eli Lilly and Company, a global pharmaceutical leader, announced breakthrough results from its 3-year Phase 3 SURMOUNT-1 study on tirzepatide (Zepbound/Mounjaro). The trial showed a 94% reduction in the risk of developing type 2 diabetes among adults with prediabetes and obesity or overweight, alongside an average 22.9% weight loss with the 15 mg dose.
• In August 2024, Dexcom, a global leader in real-time continuous glucose monitoring, launched Stelo, its first over-the-counter CGM in the U.S. Designed for people with prediabetes or type 2 diabetes not using insulin, Stelo is available for USD 99/month or USD89 via subscription and helps users track how lifestyle factors impact glucose levels.
• In June 2024, Aphaia Pharma, a clinical-stage biopharma company focused on metabolic health, reported positive Phase 2 trial results for APHD-012, its oral glucose formulation for prediabetes. The trial met its primary endpoint, showing significant improvement in glucose tolerance and a strong safety profile after six weeks of treatment.

Top Strategies Followed by Global Prediabetes Market Players

• Established players in the global prediabetes market are focusing on extensive research and development to innovate high-performance products. These companies invest heavily in R&D to develop cutting-edge solutions that cater to the evolving needs of prediabetic patients. Moreover, strategic partnerships play a crucial role in solidifying market presence.
  • For instance, in June 2024, AstraZeneca, a global biopharmaceutical company focused on innovative therapies across cardiovascular, renal, and metabolic diseases, received U.S. FDA approval for FARXIGA (dapagliflozin) to treat type 2 diabetes in pediatric patients aged 10 and above.

• Mid-level players, on the other hand, are concentrating on delivering cost-effective solutions to target price-sensitive consumers. They are focusing on developing quality products that are affordable and accessible to a wider range of patients.
  • For instance, in June 2024, Aphaia Pharma, a clinical-stage biopharma company focused on metabolic health, reported positive Phase 2 trial results for APHD-012, its oral glucose formulation for prediabetes. The trial met its primary endpoint, showing significant improvement in glucose tolerance and a strong safety profile after six weeks of treatment.

• Small-scale players are adopting niche specialization as a key strategy to differentiate themselves in the global prediabetes market. They are targeting specific market segments with unique features or innovative products that cater to the specific needs of those niches.
  • For instance, in March 2023, PharmaLinea, a leading developer of clinically supported private label nutraceuticals, launched a new product targeting the rising demand in blood glucose management. As prediabetes awareness grows—driven by increasing prevalence and the adoption of wearable health tech—the company aims to help brands capture this evolving opportunity in the prediabetes market.

Market Report Scope

Prediabetes Market Dynamics

To learn more about this report, Request sample copy

Prediabetes Market Driver - Rising global incidence of obesity and increased risk of type 2 diabetes

The global prediabetes market is significantly driven by the rising incidence of obesity worldwide, which is a major risk factor for developing type 2 diabetes. The increasing prevalence of sedentary lifestyles, unhealthy dietary habits, and lack of physical activity have contributed to the growing obesity rates across various age groups and demographics.

As the global population continues to grapple with the obesity epidemic, the risk of developing prediabetes and subsequently type 2 diabetes increases substantially. This alarming trend has created a pressing need for effective interventions, diagnostic tools, and therapeutic options to manage prediabetes and prevent its progression to full-blown diabetes, thereby fueling the growth of the global prediabetes market.

For instance, in May 2025, according to data published by WHO, one in eight people globally were affected by obesity by 2022, with adult cases doubling and adolescent cases quadrupling since 1990. Over 2.5 billion adults were overweight, including 890 million with obesity. As a chronic disease, obesity raises the risk of diabetes, heart disease, and cancer.

Prediabetes Market Opportunity: Adoption of Continuous Glucose Monitoring (CGM) and AI-powered health apps

The increasing adoption of continuous glucose monitoring (CGM) devices and AI-powered health apps presents a significant opportunity for the global prediabetes market. CGM systems provide real-time, around-the-clock monitoring of glucose levels, enabling individuals with prediabetes to gain valuable insights into their glycemic patterns and make informed decisions regarding their lifestyle and dietary choices. The integration of CGM with AI-powered health apps further enhances the potential for personalized care and early intervention. These apps can analyze the vast amounts of data generated by CGM devices, identify patterns, and provide tailored recommendations for diet, exercise, and medication management.

Moreover, AI algorithms can predict potential glucose excursions and alert users to take proactive measures, thereby empowering individuals to better manage their prediabetes and reduce the risk of complications. For instance, in April 2025, Ambrosia, a global innovator in real-time health tracking, launched India’s first 24x7 glucose and stress monitoring service. Already successful in the U.S. and Europe, the service uses AI-powered analytics, wearable sensors, and remote monitoring to offer continuous health insights, helping users manage their well-being proactively.

Analyst Opinion (Expert Opinion)

• The global prediabetes market is gaining momentum due to a confluence of factors including increased public health awareness, early screening initiatives, and the integration of digital health technologies. Governments and healthcare systems are investing heavily in preventive care as the economic burden of diabetes surges globally. AI-powered diagnostics, wearable glucose monitors, and mobile health platforms are transforming early detection and lifestyle management. However, the market faces challenges such as inconsistent diagnostic criteria across regions and limited accessibility to preventive care in low- and middle-income countries. Emerging opportunities lie in personalized digital therapeutics and cross-sector collaborations for behavior change interventions.
• Recent events such as the IDF World Diabetes Congress, American Diabetes Association (ADA) Scientific Sessions, and WHO Global Diabetes Compact Forum have fostered collaboration and accelerated policy support by focusing on early detection, equitable access, and technology deployment. Notable initiatives include the CDC’s National Diabetes Prevention Program (NDPP) in the U.S., which has scaled community-based interventions, and Novo Nordisk’s Cities Changing Diabetes programme that works with local governments to prevent diabetes through urban health strategies. These efforts collectively signal a strong global shift toward tackling prediabetes through proactive, tech-enabled, and policy-driven approaches.

Market Segmentation

•  Drug Class Insights (Revenue, USD Mn, 2020 - 2032)
• • Biguanides
    • Metformin
    • Phenformin
  • Sulfonylureas
    • Glipizide
    • Glyburide
  • Dipeptidyl Peptidase-4 (DPP-4) Inhibitors
    • Sitagliptin
    • Saxagliptin
  • Glucagon-Like Peptide-1 (GLP-1) Receptor
    • Liraglutide
    • Semaglutide
  • Thiazolidinediones (TZDs)
    • Pioglitazone
    • Rosiglitazone
  • Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors
    • Canagliflozin
    • Dapagliflozin
  • Insulin Therapy
    • Insulin Glargine
    • Insulin Lispro
  • Combination Therapies
    • Metformin + Sitagliptin
    • Metformin + Glipizide
  • Others
•  Type Insights (Revenue, USD Mn, 2020 - 2032)
• • Prescription-only Drugs
  • Over-the-Counter (OTC)
•  Routes of Administration Insights (Revenue, USD Mn, 2020 - 2032)
• • Oral
  • Subcutaneous
  • Transdermal
  • Inhalable/Intranasal
  • Others
•  Age Group Insights (Revenue, USD Mn, 2020 - 2032)
• • Children
  • Adults
  • Elderly
•  Gender Insights (Revenue, USD Mn, 2020 - 2032)
• • Male
  • Female
•  Distribution Channel Insights (Revenue, USD Mn, 2020 - 2032)
• • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Regional Insights (Revenue, USD Mn, 2020 - 2032)
• • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC Countries
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • North Africa
    • Central Africa
• Key Players Insights
  • Novo Nordisk
  • Johnson & Johnson
  • Merck & Co.
  • Sanofi
  • Eli Lilly and Company
  • AstraZeneca
  • Bayer AG
  • Abbott Laboratories
  • Boehringer Ingelheim
  • GlaxoSmithKline
  • Amgen Inc.
  • Takeda Pharmaceutical Company
  • Astellas Pharma
  • Pfizer Inc.
  • Novartis AG

Sources

Primary Research Interviews:

• Endocrinologists and Diabetologists (Private Practice & Hospital-Based)
• Healthcare IT Vendors (Developing Diagnostic Devices)
• Public Health Officials (Ministry of Health, CDC)
• Clinical Trial Investigators
• Pharmacists and Community Health Workers.

Databases:

• Centers for Disease Control and Prevention (CDC)
• World Health Organization (WHO)
• National Institutes of Health (NIH) – NIDDK
• International Diabetes Federation (IDF)
• Organisation for Economic Co-operation and Development (OECD)
• European Centre for Disease Prevention and Control (ECDC)
• Public Health England (PHE)

Magazines:

• Diabetes Technology & Therapeutics
• Pharmaceutical Technology
• Drug Development & Delivery
• Medical Device and Diagnostic Industry (MD+DI)
• Healthcare IT News

Journals:

• The Lancet Diabetes & Endocrinology
• Diabetes Care
• Diabetologia
• Journal of Clinical Endocrinology and Metabolism
• BMJ Open Diabetes Research & Care
• Nature Reviews Endocrinology

Newspapers:

• The New York Times – Health Section
• The Guardian – Global Health Reports
• Reuters Health
• BBC Health
• The Hindu – Health and Science
• The Economic Times – Healthworld

Associations:

• American Diabetes Association (ADA)
• European Association for the Study of Diabetes (EASD)
• Endocrine Society
• American Association of Clinical Endocrinology (AACE)
• Asia-Pacific Diabetes Association (APDA)

Public Domain Sources:

• Open Science Framework (OSF)
• WHO STEPwise Approach to NCD Risk Factor Surveillance (STEPS)
• National Health Interview Survey (NHIS)
• Behavioral Risk Factor Surveillance System (BRFSS)
• Google Scholar – Open Access Health Studies

Proprietary Elements:

• CMI Data Analytics Tool: Proprietary analytics tool to analyze real-time market trends, consumer behavior, and technology adoption in market
• Proprietary CMI Existing Repository of Information for Last 8 Years